China Pharma Holdings, Inc. (CPHI)
NYSEAMERICAN: CPHI · IEX Real-Time Price · USD
0.253
-0.005 (-1.90%)
At close: Jul 19, 2024, 4:00 PM
0.255
+0.003 (0.99%)
Pre-market: Jul 22, 2024, 7:39 AM EDT

China Pharma Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2007
Revenue
6.427.018.19.6410.8710.92
Upgrade
Revenue Growth (YoY)
-24.11%-13.48%-15.95%-11.27%-0.53%-11.41%
Upgrade
Cost of Revenue
7.177.298.69.298.919.44
Upgrade
Gross Profit
-0.75-0.28-0.490.351.951.48
Upgrade
Selling, General & Admin
2.282.252.963.154.044.64
Upgrade
Research & Development
0.250.240.190.320.380.23
Upgrade
Other Operating Expenses
-0.01-0.02-0.09-0.260.1217.02
Upgrade
Operating Expenses
2.522.473.063.214.5321.89
Upgrade
Operating Income
-3.27-2.75-3.55-2.86-2.58-20.41
Upgrade
Interest Expense / Income
0.30.330.430.540.290.32
Upgrade
Other Expense / Income
-0.01-0.01-0.01-0-0.01-0.03
Upgrade
Pretax Income
-3.56-3.08-3.97-3.4-2.87-20.7
Upgrade
Net Income
-3.56-3.08-3.97-3.4-2.87-20.7
Upgrade
Shares Outstanding (Basic)
1331111
Upgrade
Shares Outstanding (Diluted)
1331111
Upgrade
Shares Change
712.82%221.82%13.96%5.74%0.10%-
Upgrade
EPS (Basic)
-0.68-0.91-3.78-3.70-3.50-24.00
Upgrade
EPS (Diluted)
-0.68-0.91-3.78-3.70-3.50-24.00
Upgrade
Free Cash Flow
0.12-0.71-0.81-0.69-0.910.47
Upgrade
Free Cash Flow Per Share
0.01-0.21-0.77-0.75-1.040.54
Upgrade
Gross Margin
-11.67%-4.01%-6.09%3.62%17.97%13.57%
Upgrade
Operating Margin
-50.93%-39.25%-43.79%-29.67%-23.73%-186.82%
Upgrade
Profit Margin
-55.42%-43.91%-49.02%-35.26%-26.38%-189.51%
Upgrade
Free Cash Flow Margin
1.80%-10.14%-10.01%-7.13%-8.37%4.32%
Upgrade
EBITDA
-0.450.01-0.840.230.11-17.45
Upgrade
EBITDA Margin
-7.08%0.12%-10.34%2.39%0.98%-159.75%
Upgrade
Depreciation & Amortization
2.812.752.73.092.682.93
Upgrade
EBIT
-3.26-2.75-3.54-2.86-2.57-20.38
Upgrade
EBIT Margin
-50.81%-39.15%-43.66%-29.64%-23.67%-186.57%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).